Skip to content
Markets News
Earnings1 min read

Roche Reports 6% Nine-Month Sales Growth at Constant Rates

Makkler Newsroom
October 22, 2026 · Based on reporting by GlobeNewswire, finanzen.net

The drugmaker said demand for medicines and diagnostic solutions lifted sales, while it maintained its full-year 2026 outlook.

Key takeaways

  • Roche’s nine-month sales rose 6% at constant exchange rates to CHF 46.5 billion.
  • The company confirmed its 2026 outlook for sales and core earnings per share growth.

Roche reported CHF 46.5 billion in sales for the first nine months of 2026, up 6% at constant exchange rates and 1% in Swiss francs. Third-quarter sales rose 7% at constant rates and 8% in Swiss francs, the company said.

Pharmaceutical sales increased 7% at constant rates over the nine-month period, while Diagnostics sales rose 4%. Roche said demand for innovative medicines and diagnostic solutions drove the growth.

The company confirmed its 2026 outlook, which calls for sales growth in the mid-single digits and core earnings per share growth in the high-single digits, both at constant exchange rates. It also said it aims to increase its dividend in Swiss francs again.

Topics
ROROG.SW

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.